Breaking News
Top News
-
Spyre (SYRE) Climbs 42% as Treatment Candidate Poses ‘Best-in-Class’ Potential
-
The end of freedom of the seas: Why global shipping may never be the same
-
Stocks and Bonds Steady as Attention Turns to Iran Talks
-
France Sees Up to €6 Billion Budget Impact From Iran War
-
UN Agency Prepares Hormuz Evacuation Plan for Hundreds of Ships
-
AI Optimism Pushing Stocks Higher Despite Iran Risks: 3-Minutes MLIV
-
Ex-Swedbank CEO Bonnesen Fully Cleared in Dirty Money Case
-
Swiss Watch Exports Dipped in March Amid Iran War and High Costs
-
Commerzbank Rejects UniCredit’s ‘Hostile’ Approach
-
Primark to split from food business despite warning of Iran war impact
-
Music executive behind K-pop group BTS faces arrest in South Korea
-
Middle East Oil Pricing Is Cracking Under Pressure
-
Regeneron Pharmaceuticals (REGN) Announces Collaboration With Telix Pharmaceuticals Limited
-
Raymond James Resumes Coverage of Jazz Pharmaceuticals (JAZZ) With an Outperform Rating
-
Why Royalty Pharma Plc (RPRX) is One of the Most Undervalued Biotech Stocks to Buy Right Now
-
RBC Capital Lifts PT on Incyte Corporation (INCY) to $95 From $92
-
Is Halozyme Therapeutics (HALO) One of the Most Undervalued Biotech Stocks to Buy Right Now?
-
Cantor Fitzgerald Downgrades ADMA Biologics Inc. (ADMA) to Neutral From Overweight
-
B. Riley Lifts PT on Theravance Biopharma (TBPH) to $17 From $14
-
Guggenheim Cuts PT on Valneva SE (VALN) to $11 From $13
2026-02-05






